NASDAQ: STROSutro Biopharma Inc Stock
$0.88-0.02 (-2.22%)
Updated Apr 29, 2025
STRO Price
$0.88
Fair Value Price
N/A
Market Cap
$73.30M
52 Week Low
$0.52
52 Week High
$5.17
P/E
-0.3x
P/B
1.64x
P/S
2.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$62.04M
Earnings
-$227.46M
Gross Margin
100%
Operating Margin
-321.25%
Profit Margin
-366.6%
Debt to Equity
7.68
Operating Cash Flow
-$192M
Beta
1.38
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
STRO Overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STRO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
STRO
Ranked#272 of 462
Ranked#272 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important STRO news, forecast changes, insider trades & much more!
STRO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STRO is good value based on its book value relative to its share price (1.64x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
STRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STRO due diligence checks available for Premium users.
Valuation
STRO fair value
Fair Value of STRO stock based on Discounted Cash Flow (DCF)
Price
$0.88
Fair Value
-$0.71
Undervalued by
224.19%
STRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
-158.75x
Market
29.19x
STRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
4.37x
STRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STRO's financial health
Profit margin
Revenue
$14.8M
Net Income
-$72.4M
Profit Margin
-489.2%
STRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STRO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$387.2M
Liabilities
$342.6M
Debt to equity
7.68
STRO's short-term assets ($343.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STRO's short-term assets ($343.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$71.7M
Investing
$87.5M
Financing
-$24.0k
STRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STRO vs Biotech Stocks
Sutro Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.